

Anthrax Vaccine Work Group

**David S. Stephens, MD, FIDSA
ACIP Anthrax Vaccine Work Group**

**Advisory Committee for
Immunization Practices
February 21, 2018**

ACIP Anthrax Work Group Members

ACIP Members: David Stephens, Chair; Robert L. Atmar; Sharon Frey

Ex Officio Members: Judy Hewitt (NIH); Eric Espeland (BARDA); Alexandra Worobec (FDA); Eric Deussing (DOD); Kim Taylor (NIH); Chia-Wei Tsai (BARDA); Julianne Clifford (FDA)

Liaison Representatives: Richard Beigi (ACOG); Kathleen Neuzil (IDSA); James Campbell (AAP); Matthew Zahn (NACCHO)

Invited Consultants: Wendy Keitel; Arthur Friedlander; Phillip Pittman; Andy Pavia; Stacy Hall

CDC: William Bower, Lead

Terms of Reference

Review new data on Anthrax Vaccine Adsorbed (AVA) including:

- ❑ **New safety studies**
- ❑ **Immunogenicity, reactogenicity and logistical considerations for administering AVA via the subcutaneous versus the intramuscular route for administration as Post Exposure Prophylaxis (PEP)**
- ❑ **AVA plus CPG 7909 adjuvant data use as post-exposure prophylaxis**
- ❑ **Efficacy and immunogenicity data on dose-sparing strategies for PEP during a mass casualty incident when AVA is a limited resource**
- ❑ **Duration of antimicrobial component of PEP when given in conjunction with AVA**
- ❑ **Data on reduced booster schedule for pre-exposure prophylaxis**
- ❑ **Advise on the use of AVA and antitoxin for PEP when no effective antimicrobials are available or have an absolute contraindication**

Today's session

□ Review data on:

- IM versus SC route of administration for mass vaccination following wide-area release of *Bacillus anthracis* spores
- AVA dose-sparing strategies when demand for vaccine exceeds supply
- Duration of antimicrobial component of PEP when given in conjunction with AVA